With our PROACs, we are addressing the need for anticoagulants with lower bleeding risk that may be safe to combine with antiplatelet agents.
To prevent stroke or heart attack, more than 60 million patients worldwide could benefit from an anticoagulant (blood thinner) alone or as part of long-term combination treatment with antiplatelet drugs (aspirin or PlavixTM). This includes patients suffering from coronary artery disease and those with acute coronary syndrome.
However, current anticoagulants are associated with an increased risk of major bleeding and are not suitable for long-term combination therapy.
Our PROACs may address this large unmet medical need. Preclinical studies have shown that while our drug candidates prevent the formation of blood clots, they leave platelet function largely unaffected and are associated with significantly reduced bleeding.
The ability of Verseon's PROACs to preserve platelet function provides an explanation for their lower bleeding and may allow for PROACs to become best-in-class drugs suitable for long-term combination therapy with antiplatelet drugs.
VE-1902, the first of our two PROAC clinical candidates, is currently in a phase 1 clinical trial. The ongoing trial is a single-center, double-blinded, randomized, placebo-controlled study assessing the safety, tolerability, and hemostatic profile of VE-1902.